ERUM QAZI: Open Payments
NPI 1043625932 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,449 in 65 payments from 17 companies in 2025. Trend: 2023 $1,245 · 2024 $1,200 · 2025 $1,449
Food & beverage: $1,449
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $257 |
| Neurocrine BioSciences, Inc. | 5 | $194 |
| Axsome Therapeutics, Inc. | 12 | $186 |
| ABBVIE INC. | 7 | $185 |
| Almatica Pharma LLC | 7 | $113 |
| Lundbeck LLC | 4 | $93 |
| Teva Pharmaceuticals USA, Inc. | 4 | $85 |
| Janssen Pharmaceuticals, Inc | 3 | $56 |
| Alkermes, Inc. | 3 | $55 |
| KVK-Tech, Inc. | 1 | $52 |
Products named: REXULTI, INGREZZA, Auvelity, VRAYLAR, LOREEV XR, AUSTEDO XR, SPRAVATO, ARISTADA.
Industry payments across MO — which companies pay providers there.
